L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?
about
The role of the immune system in neurodegenerative disorders: Adaptive or maladaptive?A Role for the Brain RAS in Alzheimer's and Parkinson's DiseasesNeuronal failure in Alzheimer's disease: a view through the oxidative stress looking-glassCell-permeable parkin proteins suppress Parkinson disease-associated phenotypes in cultured cells and animalsSalvianolic acid B attenuates toxin-induced neuronal damage via Nrf2-dependent glial cells-mediated protective activity in Parkinson's disease modelsProteome analysis reveals roles of L-DOPA in response to oxidative stress in neuronsRgs6 is required for adult maintenance of dopaminergic neurons in the ventral substantia nigra.The Relationship between Parkinson Disease and Brain Tumor: A Meta-Analysis.Importance of the brain Angiotensin system in Parkinson's diseaseThe real catecholamine content of secretory vesicles in the CNS revealed by electrochemical cytometry.Anti-apoptotic effect of Shudipingchan granule in the substantia nigra of rat models of Parkinson's disease.Defective autophagy in Parkinson's disease: role of oxidative stress.Diterpenes: Advances in Neurobiological Drug Research.The Neuroprotective Effect of Erythropoietin on Rotenone-Induced Neurotoxicity in SH-SY5Y Cells Through the Induction of Autophagy.l-DOPA-induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role?Resveratrol attenuates L-DOPA-induced hydrogen peroxide toxicity in neuronal cells.Increased risk of brain tumor in patients with Parkinson's disease: a nationwide cohort study in Taiwan.Behavioral and neurochemical effects of alpha-lipoic Acid in the model of Parkinson's disease induced by unilateral stereotaxic injection of 6-ohda in rat.Engineering of a bacterial tyrosinase for improved catalytic efficiency towards D-tyrosine using random and site directed mutagenesis approaches.Evaluation of levodopa and carbidopa antioxidant activity in normal human lymphocytes in vitro: implication for oxidative stress in Parkinson's disease.Modulation of PC12 cell viability by forskolin-induced cyclic AMP levels through ERK and JNK pathways: an implication for L-DOPA-induced cytotoxicity in nigrostriatal dopamine neurons.Combination Treatment of Icariin and L-DOPA Against 6-OHDA-Lesioned Dopamine Neurotoxicity.On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease.
P2860
Q26861263-71F8144A-D87A-42FD-A7C0-2E2DA32C7071Q26861984-B4669347-6BFF-403B-AB59-ACE1845EC8B5Q27015785-EFDA1C88-D98D-43C9-B2B2-EE56DAD7996FQ27318797-D417DA26-087E-433E-8461-A8583230D9D4Q28540349-48EF052E-58C1-463D-B2CA-548DD0029138Q34017856-04A18454-35DC-4587-B7D0-3C43AB39C227Q34679823-6584A124-F6B1-4C4C-B046-D9B06C83A933Q36169142-F2985120-FAE8-4E84-ABF9-3E2FDBB4F5BFQ36415423-7A2C96CD-B4A0-4B63-B626-6020F4F7C66DQ36682309-ACABC632-CC80-444F-9FDA-97386AEADC72Q37425231-D249F20D-2296-4A2C-9AC3-BF6C77ED716EQ38035191-DE006D74-8FED-4212-A882-E9E6F9FAEFA7Q38791506-2F43B7A6-8AC3-4CD4-8B94-BFB3C6BC6C2EQ38986871-FC0CD7AE-2F43-48D4-A8DE-C3DF3107FCEBQ39012371-FA31AE05-5D75-48CE-926B-9F4B55DCA449Q39251059-25C1A8FE-59C3-4E93-BDB5-9C10322360C0Q40385346-CBC96B7D-D077-4B53-916A-B6216C379BCCQ41828082-18A94E79-3B68-42D5-A181-8EB55D1FF0C8Q44707154-6745C787-889D-4341-BEFD-CFB47274081CQ48471259-A53280C2-F9CB-4D92-8ED0-D6DA5E743A91Q48545452-5B1FF9E7-8D3E-4B16-A6CF-B2B4141D4708Q55118987-EE658184-81A2-4429-91CB-15FFA5C0A030Q55432445-B258139C-41C5-49D9-BADB-DC836B69E1F7
P2860
L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?
@en
L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?
@nl
type
label
L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?
@en
L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?
@nl
prefLabel
L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?
@en
L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?
@nl
P50
P1476
L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?
@en
P2093
Giorgio Bernardi
P304
P356
10.1016/J.PNEUROBIO.2011.06.005
P577
2011-06-24T00:00:00Z